Piper Sandler analyst David Amsellem initiated coverage of Karuna Therapeutics with an Overweight rating and $285 price target. The analyst believes Karuna’s KarXT is poised to emerge as "valued and versatile" option in a schizophrenia space that has been "starved for mechanistically unique options." Peak U.S. sales approaching $3B are realistic, Amsellem tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KRTX: